EP4260852A1 — Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating
Assigned to Dr August Wolff GmbH and Co KG Arzneimittel · Expires 2023-10-18 · 3y expired
What this patent protects
The present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis, wherein administration of the formulation to the patient comprises: a) an initial phase with a topical admini…
USPTO Abstract
The present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis, wherein administration of the formulation to the patient comprises: a) an initial phase with a topical administration of a predetermined amount of the formulation 5 to 7 times per week for a total time period of less than six months; followed by b) a maintenance phase with a topical administration of the same amount of the formulation 1 to less than 5 times per week.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.